NCT02265159UnknownPhase 2
Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- University of Zurich
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Oncological safety
Study Overview
Brief Summary
The investigators aim to evaluate cancer control, genitourinary, rectal and overall health-related quality of life outcomes and effectiveness of focal therapy for localised prostate cancer using High Intensity Focused Ultrasound (HIFU).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to 99 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically proven prostate cancer on trans-rectal or transperineal template prostate biopsies
- •Template biopsy:
- •unilateral disease (Gleason ≤4+3)
- •bilateral disease: presence of clinically significant cancer in both sides (Gleason ≤4+3) OR clinically insignificant disease with a burden of >50% of biopsy cores taken on that side, OR bilateral clinically insignificant disease and <50% of biopsy cores positive on any one side but with dominant disease burden on one side
- •Stage T1-T2cN0M0 disease, as determined by local guidelines (radiological T3a permitted)
- •Serum PSA ≤15
- •Life expectancy of ≥10 years
- •Signed informed consent by patient
- •An understanding of the German language sufficient to understand written and verbal information about the trial and consent process
Exclusion Criteria
- •Men who have had androgen suppression/hormone treatment within the previous 12 months for their prostate cancer
- •Men with evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging
- •Men with an inability to tolerate a transrectal ultrasound
- •Men with latex allergies as the HIFU probe is covered with a latex condom sheath prior to insertion into the back passage
- •Men who have undergone prior significant rectal surgery preventing insertion of trans-rectal HIFU probe (decided on the type of surgery in individual cases)
- •Men who have had previous HIFU, cryosurgery, thermal or microwave therapy to the prostate.
- •Men who have undergone a Transurethral Resection of the Prostate (TURP) for symptomatic lower urinary tract symptoms within 6 months. These patients may be included within the trial if deferred from consenting and screening until at least 6 months following the TURP.
- •Men not fit for major surgery as assessed by a Consultant Anaesthetist
- •Men unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant etc likely to contribute significant artefact to images)
- •Presence of metal implants/stents in the urethra
- •Presence of prostatic calcification and cysts (on transrectal ultrasound) whose location will interfere with effective delivery of HIFU therapy
- •Men with renal impairment with a glomerular filtration rate of <35ml/min (unable to tolerate Gadolinium dynamic contrast enhanced MRI).
Arms & Interventions
Focal Therapy Using High Intensity Focused Ultrasound
Other
Intervention: Focal Therapy Using High Intensity Focused Ultrasound (Procedure)
Outcomes
Primary Outcomes
Oncological safety
Time Frame: 36 months
To determine the proportion of men who are free of clinically significant prostate cancer in the treated area AND are free of clinically significant prostate cancer in the untreated area 36 months after focal therapy using HIFU
Secondary Outcomes
- Lower urinary tract symptoms(36 months)
- Anxiety(36 months)
- Bowel function(36 months)
- Erectile function(36 months)
- Continence(36 months)
- Biochemical failure(36 months)
- Health care costs(36 months)
- Sensitivity and specificity of MRI imaging(36 months)
- Orgasmic function(36 months)
- Sexual function(36 months)
- Secondary intervention(36 months)
- Quality of life(36 months)
- General histological outcome(36 months)
Investigators
Daniel Eberli
PD Dr. med. PhD
University of Zurich
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal CancerNasopharyngeal NeoplasmsNCT00577057Hospital Authority, Hong Kong798
Recruiting
Not Applicable
Clinical Trial of Approaches to Prostate Cancer SurgeryProstate CancerNCT05155501Weill Medical College of Cornell University600
Recruiting
Phase 2
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary ArteriesMyocardial Bridge of Coronary ArteryAngina PectorisMicrovascular AnginaVasospastic AnginaNCT06424834Stanford University150
Unknown
Not Applicable
EXtendedAnalysis for Cancer TreatmentMalignant Solid TumorNCT02999750Medical University of Vienna55
Completed
Phase 3
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT00379262Hong Kong Nasopharyngeal Cancer Study Group Limited803